The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic f... The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified. Show more
EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION PR Newswire OKLAHOMA CITY, Oct. 23, 2023 OKLAHOMA CITY, Oct. 23, 2023 /PRNewswire/ -- Exchange Traded Concepts, LLC...
CHNA offers diversified exposure to leading companies in China’s burgeoning BioPharma industry Today, the Loncar China BioPharma ETF (Nasdaq: CHNA) begins trading on the Nasdaq in the...
CNCR offers diversified exposure to 30 leading companies with immunotherapy focus The Loncar Cancer Immunotherapy ETF (Nasdaq: CNCR) recently surpassed $50 million in assets under...
Three Biotechnology Companies Added to the Index Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy...
Gilead and NewLink Added to the Only Index that Tracks Cancer Immunotherapy Loncar Investments, LLC today announced two new additions to the Loncar Cancer Immunotherapy Index, a group of...
Three Biotechnology Companies Added to the Index Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy...
ADVISORY, Oct. 28, 2016 (GLOBE NEWSWIRE) -- What: Exchange Traded Concepts, Loncar Investments, and Cancer Research Institute will visit the Nasdaq MarketSite in Times Square to...
Cancer immunotherapy companies are beneficially disrupting status quo cancer treatments by deploying body’s own immune system to fight disease ETF offers diversified exposure to both...
Two New Immunotherapy Companies Added to the Index Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy...
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.365 | -10.4079298513 | 13.115 | 13.3 | 11.69 | 2731 | 12.71135651 | SP |
4 | -1.13 | -8.77329192547 | 12.88 | 13.3 | 11.69 | 4014 | 12.41978344 | SP |
12 | -3.61 | -23.5026041667 | 15.36 | 15.94 | 11.69 | 3343 | 13.64819958 | SP |
26 | -3.35 | -22.1854304636 | 15.1 | 16.27 | 11.69 | 3605 | 14.42219014 | SP |
52 | -2.27 | -16.1911554922 | 14.02 | 18 | 11.69 | 13735 | 15.66464257 | SP |
156 | -10.08 | -46.1749885479 | 21.83 | 21.83 | 9.22 | 8976 | 15.20124352 | SP |
260 | -12.45 | -51.4462809917 | 24.2 | 35.818 | 9.22 | 9233 | 20.16906804 | SP |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales